Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, April 10, 2023
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
Mayank Mamtani Maintained (XFOR) at Strong Buy with Decreased Target to $3 on, Apr 10th, 2023
Mayank Mamtani of B. Riley Securities, Maintained "X4 Pharmaceuticals, Inc." (XFOR) at Strong Buy with Decreased Target from $7 to $3 on, Apr 10th, 2023.
Mayank has made no other calls on XFOR in the last 4 months.
There are 4 other peers that have a rating on XFOR. Out of the 4 peers that are also analyzing XFOR, 0 agree with Mayank's Rating of Hold.
These are the ratings of the 4 analyists that currently disagree with Mayank
- Leland Gershell of "Oppenheimer" Maintained at Buy with Decreased Target to $4 on, Friday, March 24th, 2023
- Swayampakula Ramakanth of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $3 on, Wednesday, March 22nd, 2023
- Kristen Kluska of "Cantor Fitzgerald" Maintained at Buy and Held Target at $3 on, Wednesday, March 22nd, 2023
- Edward Tenthoff of "Piper Sandler" Initiated at Buy and Held Target at $3 on, Monday, December 12th, 2022
